Scientists track immune changes in MS patients on B-Cell drugs
NCT ID NCT06586177
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This study follows 100 people with relapsing-remitting multiple sclerosis who are taking B-cell therapies like ofatumumab or ocrelizumab. Researchers will regularly check their immune cells, proteins, and brain scans to see how these treatments affect the body over time. The goal is to better understand why some patients experience a 'durable effect' and others do not.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Heinrich-Heine University, Duesseldorf
RECRUITINGDüsseldorf, 40225, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.